Arrowhead Pharmaceuticals, Inc. (ARWR)
62.75
+2.01
(+3.31%)
USD |
NASDAQ |
Oct 09, 16:00
62.58
-0.17
(-0.27%)
Pre-Market: 20:00
Arrowhead Pharmaceuticals Cash from Operations (Quarterly) : -177.47M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -177.47M |
| March 31, 2026 | 84.44M |
| December 31, 2025 | 13.48M |
| September 30, 2025 | 20.49M |
| June 30, 2025 | -149.72M |
| March 31, 2025 | 460.05M |
| December 31, 2024 | -151.27M |
| September 30, 2024 | -137.22M |
| June 30, 2024 | -115.42M |
| March 31, 2024 | -92.38M |
| December 31, 2023 | -117.84M |
| September 30, 2023 | -25.26M |
| June 30, 2023 | -21.45M |
| March 31, 2023 | -31.67M |
| December 31, 2022 | -75.52M |
| September 30, 2022 | -68.67M |
| June 30, 2022 | -68.85M |
| March 31, 2022 | 62.73M |
| December 31, 2021 | -61.35M |
| September 30, 2021 | -24.12M |
| June 30, 2021 | -29.61M |
| March 31, 2021 | 263.87M |
| December 31, 2020 | -38.92M |
| September 30, 2020 | -10.85M |
| June 30, 2020 | -33.43M |
| Date | Value |
|---|---|
| March 31, 2020 | -27.58M |
| December 31, 2019 | -23.53M |
| September 30, 2019 | 13.81M |
| June 30, 2019 | 10.53M |
| March 31, 2019 | -19.59M |
| December 31, 2018 | 168.28M |
| September 30, 2018 | -2.680M |
| June 30, 2018 | -14.41M |
| March 31, 2018 | -15.44M |
| December 31, 2017 | -14.69M |
| September 30, 2017 | -9.204M |
| June 30, 2017 | -10.41M |
| March 31, 2017 | -14.33M |
| December 31, 2016 | 10.00M |
| September 30, 2016 | -10.18M |
| June 30, 2016 | -18.35M |
| March 31, 2016 | -14.75M |
| December 31, 2015 | -21.15M |
| September 30, 2015 | -12.02M |
| June 30, 2015 | -13.12M |
| March 31, 2015 | -16.37M |
| December 31, 2014 | -24.20M |
| September 30, 2014 | -10.92M |
| June 30, 2014 | -9.776M |
| March 31, 2014 | -7.698M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Moderna, Inc. | -526.00M |
| Sarepta Therapeutics, Inc. | 197.07M |
| Revolution Medicines, Inc. | -387.32M |
| Intellia Therapeutics, Inc. | -83.11M |
| Denali Therapeutics, Inc. | -97.00M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 43.68M |
| Cash from Financing (Quarterly) | -0.449M |
| Free Cash Flow | -75.11M |
| Free Cash Flow Per Share (Quarterly) | -1.265 |
| Free Cash Flow to Equity (Quarterly) | -184.24M |
| Free Cash Flow to Firm (Quarterly) | -156.76M |
| Free Cash Flow Yield | -0.85% |